Sun Pharma Q4 Net Profit Drops 19% to ₹2,154 Crore; Declares ₹5.50 Final Dividend for FY25

Sun Pharmaceutical Industries Ltd reported its financial results for the fourth quarter ended March 31, 2025, revealing a dip in profitability despite strong revenue growth.

In Q4FY25, Sun Pharma’s consolidated net profit fell by 19% to ₹2,153.9 crore, compared to ₹2,658.7 crore in the same quarter last year. The dip in net profit comes even as the company saw solid growth in its overall business operations.

Revenue Rises Despite Profit Decline

While the net profit declined, Sun Pharma’s total consolidated revenue from operations rose by 8.1%, reaching ₹12,958.8 crore during the quarter, up from ₹11,983 crore in the year-ago period.

This suggests that while operational performance improved, other cost pressures may have weighed on the bottom line.

Dividend Announcement Brings Cheer to Shareholders

The company’s board has declared a final dividend of ₹5.50 per share for the financial year FY25. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).

“The Board has recommended a final dividend of ₹5.50 per equity share of ₹1 each,” the company said in a statement.

The record date for determining eligible shareholders is set for Monday, 7 July 2025. If approved, the dividend will be paid on or before Friday, 8 August 2025.

EBITDA Growth Shows Operational Strength

Sun Pharma also showed a healthy improvement in its operational earnings. The company’s EBITDA (Earnings Before Interest, Tax, Depreciation and Amortization) grew by 22.4% to ₹3,715.9 crore in Q4FY25, compared to ₹3,035.15 crore in the same quarter last year.

EBITDA margins also improved significantly, standing at 28.7%, up from 25.3% YoY, indicating stronger efficiency and profitability from core operations.

Stock Performance

Despite the mixed earnings report, shares of Sun Pharmaceutical Industries Ltd closed marginally lower in Thursday’s trade. The stock ended the day at ₹1,724.7 per share on the NSE, down 0.41%.

This Q4 performance highlights a mixed bag for Sun Pharma — with strong revenue and EBITDA growth, but declining net profit due to one-time factors. The final dividend announcement and improving operational margins, however, signal the company’s continued focus on delivering value to its shareholders.